HK Stock MarketDetailed Quotes

02137 BRII-B

Watchlist
  • 0.910
  • -0.020-2.15%
Market Closed Mar 28 16:08 CST
663.97MMarket Cap-3446P/E (TTM)

About BRII-B Company

Tengshengbo Pharmaceutical is a commercial-stage biotechnology company dedicated to developing treatment solutions to major public health challenges because of the vast unmet medical needs, limited choices, and serious social stigma in these areas. Established in 2018, our journey began by harnessing the potential of breakthrough innovation and valuable patient insight to expand patient choice and access. The company is developing a broad pipeline of therapeutic candidates, focusing on infectious diseases and central nervous system diseases. We are leading the clinical development of functional treatments for a wide range of hepatitis B patients in China, and the potential for pioneering similar treatments for postpartum depression and major depression in the US. Furthermore, we are accelerating the next phase of enterprise development and preparing to provide clinically differentiated preventive vaccines for susceptible adults in the Asia-Pacific region to prevent hepatitis B infection. This multi-level development direction is based on the company's own internal development and strategic cooperation with world-renowned partners, enabling us to create differentiated treatment plans that meet the needs of different patients. Our approach is based on the application of novel chemical and sustained-release agents, and the development of combination therapies that take into account the complex nature of complex diseases. China is the world's largest HBV market, with 87 million infected people and 200 million susceptible people. Our company is committed to ending hepatitis B from prevention to cure. Through strategic licensing partnerships with Vir Biotechnology, Inc., and VBI Vaccines Inc., a promising product line has been established, which includes clinically differentiated prophylactic vaccines, and asset product lines under development to improve the functional cure rate of HBV patients. Novel combination therapies targeting specific subgroups of HBV patients may improve functional cure rates for all HBV patient groups and may improve treatment decision-making and adoption rates. Inspired by the scientific insight of our visionary leadership team and continuously updated data, we are exploring a wide range of potential combination treatment options to improve the possibility of achieving high HBV functional cure rates. For the US team, we focus primarily on the area of central nervous system treatment and aim to redefine treatment for PPD and MDD by improving patient choices. The company is developing a novel GABAA receptor PAM, a first-of-its-kind long-acting agent that can be used as a monotherapy for PPD and MDD. In-depth understanding of patients suggests that providing a single treatment option for people with PPD or MDD will bring about change for patients, because compared with existing treatments, this treatment can reduce the burden of follow-up treatment for mental illness, greatly improve accessibility, compliance, and convenience, and reduce the impact of social stigma. Based on our in-depth understanding of patients, the company is working to expand the treatment options for PPD and MDD to provide patients with the option of one-time injection therapy. The company is working closely with leading patient rights organizations in the US to ensure that the needs of a wide range of patients with unique perspectives and experiences are met. The needs of patients of different races, nationalities, nationalities, religions, and socioeconomic statuses may vary greatly. The company also has global rights to a novel polymyxin to treat multi-drug resistant and broadly drug-resistant gram-negative bacterial infections, as well as rights in Greater China for non-tuberculous mycobacterial lung disease. Initially, it focused on refractory mycobacterial complex bacteria. These drugs were all clinically developed by its partners. Additionally, the company is exploring collaborative opportunities to develop future HIV drug candidates discovered within the US. All of these diseases are in great demand for new and innovative treatment options. In addition to pipeline development, we continue to promote a patient-centered approach and strengthen relationships with patients, patient caregivers, and patient rights organizations. We continue to strengthen our partnerships with leading US maternal health advocacy groups through active participation and sponsorship of various activities. These activities and industry recognition further reinforce our commitment to ensure that patients' voices are heard and understood throughout the discovery and development process, from R&D to commercialization. At the core of our culture are unwavering values — putting patients first, cultivating trust, maintaining integrity, and ensuring quality in everything we do. Across major healthcare markets, Tengshengbo Pharmaceutical operates in Raleigh-Durham, the San Francisco Bay Area, Beijing, and Shanghai. As a dynamic multinational company, we have formed strong teams in China and the US to promote cooperation and collaboration and advance our collective mission. By steadfastly fulfilling our mission and values, we are shaping the industry landscape, leading patient-centered innovation, and striving to close critical gaps in patient treatment and prevention. As we continue to evolve, we remain committed to making a meaningful impact, driving us to create transformative change and contribute to improving global health.

Company Profile

Symbol02137
Company NameBRII-B
ISINKYG1645A1094
Listing Date07/13/2021
Issue Price22.25
Shares Offered111.58M share
Founded12/08/2017
RegistrationCayman Islands
ChairmanZhi HONG
SecretaryYongzi\liankang He
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands
Head Office and Principal Place of Business5/F, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees128
MarketHong Kong motherboard
Emailinfo@BriiBio.com
Business Tenshengbo Pharmaceutical Biotechnology Co., Ltd. is a biotechnology company headquartered in China and the United States mainly engaged in the research and development of infectious disease therapeutics. The company's products are used in infectious diseases such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multidrug-resistant (MDR) or broadly resistant (XDR) gram-negative infections) and other diseases with significant public health burdens (such as central nervous system (CNS) diseases). The company is also developing treatments for COVID-19, etc.

Company Executives

  • Name
  • Position
  • Salary
  • Zhi HONG
  • Chairman of the Board,Nomination Committee Member,CEO,Executive Director
  • --
  • Robert Taylor NELSEN
  • Strategy Committee Member,Non-Executive Director
  • --
  • Martin J Murphy JR
  • Remuneration Committee Chairman,Independent Non-Executive Director,Nomination Committee Member
  • --
  • Grace Hui TANG
  • Remuneration Committee Member,Independent Non-Executive Director,Co-Chairman of the Risk Committee,Audit Committee Chairman
  • --
  • Yaohua Xu
  • Audit Committee Member,Independent Non-Executive Director,Remuneration Committee Member,Risk Committee Members
  • --
  • Li Yan
  • Chief Medical Officer
  • --
  • Taiying Yang
  • Independent Non-Executive Director,Strategy Committee Member,Co-Chairman of the Audit Committee,Co-Chairman of the Risk Committee
  • --
  • Ankang Li
  • Authorized Representative,Strategy Committee Chairman,Executive Director,Joint Company Secretary,CFO
  • --
  • Susannah Cantrell
  • Chief Business Officer
  • --
  • Gregg Huber ALTON
  • Independent Non-Executive Director,Strategy Committee Member,Nomination Committee Chairman
  • --
  • Lianhong Xu
  • Senior Vice President (Head of Medicinal Chemistry R&D)
  • --
  • Eleanor (Ellee) de Groot
  • chief technology officer
  • --
  • Qing Zhu
  • Senior Vice President (Biopharmaceutical Division Head),Head of R&D in China
  • --
  • David MARGOLIS
  • VP
  • --
  • Yongzi He
  • Authorized Representative,Joint Company Secretary
  • --
  • Karen D. NEUENDORFF
  • Chief Talent Officer
  • --
  • Aleksandar Skuban
  • VP
  • --
  • Coy STOUT
  • Director of Patient Advocacy
  • --
  • Xu Liang
  • General Manager of Greater China
  • --
  • Brian Alvin Johns
  • Chief Scientific Officer
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg